FDA Approves LYTENAVA (BLA761320) for Use
The FDA has approved LYTENAVA, a new formulation of bevacizumab, under application BLA761320.
Company
Pharmaceutical intelligence for OUTLOOK THERAPEUTICS, INC. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.